December 27, 2015
5 min watch
Save

VIDEO: Speaker — Early anti-VEGF treatment yields better final outcomes in CNV

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FLORENCE, Italy — At the FLOREtina meeting, Young-Hee Yoon, MD, PhD, gives her views on when to start and how long to continue anti-VEGF treatment for myopic choroidal neovascularization. Based on 5-year follow-up data, Yoon addresses questions that were not resolved in pivotal trials.